Literature DB >> 18554361

A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy.

Fritz Zimprich, Elisabeth Stogmann, Silvia Bonelli, Christoph Baumgartner, Jakob C Mueller, Thomas Meitinger, Alexander Zimprich, Tim M Strom.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18554361     DOI： 10.1111/j.1528-1167.2008.01549_4.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN： 0013-9580            Impact factor:   5.864


× No keyword cloud information.
  13 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up.

Authors:  Bo-Ting Zhou; Qiu-Hong Zhou; Ji-Ye Yin; Guo-Liang Li; Jian Qu; Xiao-Jing Xu; Ding Liu; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  CNS Neurosci Ther       Date:  2012-05-17       Impact factor: 5.243

3.  Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population.

Authors:  Ram Lakhan; Ritu Kumari; Usha K Misra; Jayanti Kalita; Sunil Pradhan; Balraj Mittal
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Genetic biomarkers in epilepsy.

Authors:  Yvonne G Weber; Anne T Nies; Matthias Schwab; Holger Lerche
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

5.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

6.  SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs.

Authors:  Christopher H Thompson; Kristopher M Kahlig; Alfred L George
Journal:  Epilepsia       Date:  2011-03-31       Impact factor: 5.864

7.  Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker.

Authors:  Emily V Fletcher; Dimitri M Kullmann; Stephanie Schorge
Journal:  J Biol Chem       Date:  2011-09-02       Impact factor: 5.157

8.  Influence of the SCN1A IVS5N + 5 G>A Polymorphism on Therapy with Carbamazepine for Epilepsy.

Authors:  Z Sterjev; G Kiteva; E Cvetkovska; I Petrov; I Kuzmanovski; Tj Ribarska; Ka Nestorovska; N Matevska; S Trajkovik-Jolevska; Aj Dimovski; Lj Suturkova
Journal:  Balkan J Med Genet       Date:  2012-06       Impact factor: 0.519

9.  SCN1A and SCN1B gene polymorphisms and their association with plasma concentrations of carbamazepine and carbamazepine 10, 11 epoxide in Iranian epileptic patients.

Authors:  Soha Namazi; Negar Azarpira; Katayoon Javidnia; Mehrdad Emami; Rahimeh Rahjoo; Razieh Berahmand; Afshin Borhani-Haghighi
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

10.  Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients.

Authors:  Armond Daci; Giangiacomo Beretta; Driton Vllasaliu; Aida Shala; Valbona Govori; Giuseppe Danilo Norata; Shaip Krasniqi
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.